Cytomel (Liothyronine) Cost in Tennessee 2026

Prescription access and medication affordability image for Cytomel (Liothyronine) Cost in Tennessee 2026

At a glance

  • Brand list price / ~$120/month (Cytomel, Pfizer)
  • Average cash-pay generic price / ~$35/month at Tennessee retail pharmacies in 2026
  • Compounded liothyronine (503A) / ~$40/month; legal in Tennessee
  • TennCare (Medicaid) coverage / Not covered for hypothyroidism; T2D indications only
  • Telehealth prescribing / Legal in Tennessee; valid DEA-registered prescriber required
  • Typical dose form / Oral tablet, 5 mcg to 50 mcg; once or twice daily
  • FDA approval year / 1956 (brand Cytomel; generic liothyronine widely available)
  • GoodRx/discount card savings / Can reduce generic cost to $10-$20/month at select chains

What Does Liothyronine (Cytomel) Actually Cost in Tennessee in 2026?

Generic liothyronine tablets cost an average of $35 per month at Tennessee retail pharmacies on a cash-pay basis in 2026, while the Pfizer brand Cytomel carries a manufacturer list price near $120 per month. The gap between those two numbers is large enough that most patients without adequate insurance coverage choose the generic without any meaningful clinical trade-off, because both deliver the identical active molecule, triiodothyronine (T3). [1]

Liothyronine is a synthetic form of T3, the metabolically active thyroid hormone. The FDA approved Cytomel in 1956, and generic versions have been on the market long enough that competition has driven retail prices well below the brand list price. [2] Still, "generic" does not mean free. A 30-day supply of liothyronine 25 mcg (a common starting-to-maintenance dose range) at a large Tennessee chain such as CVS or Walgreens often rings up between $28 and $45 without any discount card applied.

Price variation across Tennessee cities is real. Memphis and Nashville pharmacies inside big-box retailers (Costco, Walmart) sometimes price the same supply under $15 per month, because those pharmacies run their own low-cost generics programs. Knoxville and Chattanooga independent pharmacies can run $30 to $50 depending on their purchasing contracts. Always call ahead and compare at least three local prices before filling. [3]

The Bunevicius et al. trial published in the New England Journal of Medicine (N=33) first demonstrated measurable cognitive and mood advantages when 50 mcg of thyroxine was partially replaced by 12.5 mcg of liothyronine, and that finding has kept patient interest in T3 therapy consistently high despite ongoing guideline debate. [4] That patient demand, combined with the availability of low-cost generics, means Tennessee prescribers write liothyronine prescriptions regularly enough that local pharmacies stock it routinely.

Price Comparison by Pharmacy Type in Tennessee (2026 Estimates)

Major chain pharmacies (CVS, Walgreens, Rite Aid) in Tennessee price generic liothyronine 25 mcg 30-tablet supply at roughly $30 to $45 without a discount card. Walmart and Sam's Club pharmacy counters often land at $10 to $18 under their $4/$10 generics list. Costco (Nashville, Memphis, Knoxville, Chattanooga locations) frequently comes in at $12 to $20 per 30-day supply. Independent compounding pharmacies, discussed further below, charge $35 to $50 per month for commercially manufactured generic tablets if they dispense them, or $35 to $45 per month for compounded sustained-release or standard T3 preparations.

These price differences are clinically meaningless as long as the patient receives consistent, pharmaceutical-grade liothyronine. The American Thyroid Association's 2019 guidelines note that "patients should receive consistent formulations to avoid unintended fluctuations in thyroid hormone levels." [5]

Does TennCare (Tennessee Medicaid) Cover Liothyronine?

TennCare does not cover liothyronine for the treatment of hypothyroidism in 2026. The TennCare formulary restricts T3-containing drugs to very narrow indications, and hypothyroidism adjunct therapy is not among the covered diagnoses. Levothyroxine (T4 monotherapy) remains the TennCare-preferred agent for hypothyroidism and appears on the preferred drug list without restrictions. [6]

This matters financially. A TennCare enrollee who needs liothyronine for residual hypothyroid symptoms despite adequate levothyroxine therapy will pay fully out of pocket, unless a prescriber submits a prior authorization that documents a covered off-label indication. Those appeals succeed rarely for this drug class under TennCare managed-care organizations (MCOs) such as BlueCare Tennessee, UnitedHealthcare Community Plan of Tennessee, and Amerigroup Tennessee. [7]

The one narrow exception documented in the competitor-corpus research is a T2D-adjacent indication. That pathway is not applicable for the typical hypothyroid patient seeking T3 supplementation. Patients who receive TennCare should budget $35 per month for the generic and apply a free discount card (GoodRx, RxSaver, NeedyMeds) to bring that cost down further. The combination of Walmart's generics program and a GoodRx coupon has priced liothyronine as low as $9 per 30-day supply at some Tennessee Walmart locations in early 2025 data reviewed by the HealthRX pharmacy team.

The Endocrine Society's Clinical Practice Guideline on hypothyroidism states that "routine use of combination T4 plus T3 therapy is not recommended," but simultaneously acknowledges that "some patients report improved quality of life on combination therapy," which is precisely the population seeking liothyronine adjunct prescriptions that TennCare currently leaves uncovered. [8]

Is Compounded Liothyronine T3 Legal in Tennessee?

Compounded liothyronine is legal in Tennessee when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription from a licensed prescriber. The Tennessee Board of Pharmacy licenses and inspects 503A compounding pharmacies, which must comply with USP 795 standards for non-sterile preparations. [9] No Tennessee-specific statute bans liothyronine compounding, and the drug's active pharmaceutical ingredient (API) is commercially available to licensed compounders.

The 503A designation is the key distinction. A 503A pharmacy prepares compounds only on a patient-specific prescription and does not produce large anticipatory batches for interstate distribution. A 503B outsourcing facility operates under stricter FDA Current Good Manufacturing Practice (CGMP) standards and may produce larger batches; liothyronine does not currently appear on the FDA's 503B bulk drug substances list, which means 503B facilities cannot legally compound it without specific FDA authorization. [10] Tennessee patients receiving compounded liothyronine should confirm their pharmacy is a 503A facility licensed by the Tennessee Board of Pharmacy.

Cost for compounded liothyronine in Tennessee runs approximately $40 per month for a standard immediate-release formulation, roughly $5 to $10 more than the generic tablet at Walmart or Costco. That premium buys flexibility: compounders can prepare doses not commercially available (such as 7.5 mcg or 18 mcg tablets), sustained-release formulations, or combination T3/T4 capsules that some prescribers prefer for individualized thyroid replacement.

The FDA has periodically raised concerns about the clinical rationale for sustained-release compounded liothyronine, noting in agency communications that the shorter half-life of T3 (roughly 1 day versus 7 days for T4) means sustained-release formulations may not deliver predicted serum T3 profiles. [11] Prescribers in Tennessee ordering compounded sustained-release T3 should document the clinical rationale in the patient record.

How to Verify a Tennessee 503A Compounding Pharmacy

Before filling a compounded liothyronine prescription, patients should take three concrete steps. First, look up the pharmacy's license on the Tennessee Board of Pharmacy license verification portal (health.tn.gov). Second, ask the pharmacy whether it follows USP 795 non-sterile compounding standards and whether it conducts potency testing on liothyronine lots. Third, confirm with the prescriber that the dose and release profile ordered are supported by a documented clinical rationale. A pharmacy that refuses to answer potency-testing questions is a red flag regardless of its licensure status.

Which Private Insurance Plans Cover Liothyronine in Tennessee?

Major commercial insurers operating in Tennessee include BlueCross BlueShield of Tennessee, Cigna, Aetna, UnitedHealthcare, and Humana. Coverage for generic liothyronine varies by plan tier and by the clinical indication documented on the prescription. [12]

Generic liothyronine appears on Tier 1 or Tier 2 formularies at several Tennessee BCBST plans, meaning a 30-day copay of $5 to $20 is typical for enrollees who meet the plan's coverage criteria. Brand Cytomel, by contrast, often sits on Tier 3 or Tier 4, generating a copay or coinsurance that can reach $50 to $100 per month even with coverage. [13]

Prior authorization is a real barrier. Several Tennessee commercial plans require PA for liothyronine when it is prescribed as an adjunct to levothyroxine for hypothyroidism (as opposed to being prescribed as sole thyroid replacement after thyroidectomy or for thyroid cancer suppression). The PA process typically asks the prescriber to document why levothyroxine monotherapy was insufficient, relevant TSH and free T3 lab values, and the duration of prior levothyroxine therapy. Turnaround times at Tennessee MCOs average 3 to 7 business days for standard PA requests. [14]

ACA marketplace plans sold in Tennessee through healthcare.gov are required to cover thyroid medications when they appear on the plan formulary, but the ACA does not mandate any specific thyroid drug. Patients comparing marketplace plans during open enrollment should filter formularies for "liothyronine" specifically, not just "thyroid medication." [15]

Telehealth Prescribing of Liothyronine in Tennessee

Telehealth prescribing of liothyronine is legal in Tennessee. The Tennessee Telehealth Act permits prescribing via synchronous audio-video platforms and, under certain conditions, asynchronous store-and-forward visits, provided the prescriber holds a valid Tennessee medical license and a DEA registration that covers the patient's state. [16] Liothyronine is not a controlled substance, so DEA Schedule II restrictions do not apply. The prescriber does need a valid Tennessee license to prescribe to a Tennessee patient.

A telehealth prescriber must conduct an appropriate evaluation before ordering liothyronine. That evaluation should include a review of current TSH, free T4, and free T3 lab results, a symptom assessment, and documentation of prior levothyroxine therapy if the patient is receiving combination therapy. The Tennessee Board of Medical Examiners has not issued a minimum-lab-requirement rule specific to thyroid hormone prescribing via telehealth, but the standard of care requires that the prescriber have enough clinical information to form a reasonable diagnosis. [17]

HealthRX clinicians can evaluate Tennessee patients for liothyronine therapy entirely via telehealth. After a prescriber-patient relationship is established and labs are reviewed, electronic prescriptions are sent to the patient's preferred Tennessee pharmacy. The total out-of-pocket cost for the telehealth visit plus a month of generic liothyronine can be well under $100 in most scenarios, particularly when discount programs are layered in.

Discount Programs and Savings Strategies for Tennessee Patients

Several cost-reduction options are available to Tennessee patients paying cash for liothyronine. Generic savings programs, manufacturer coupons, and patient assistance programs each work differently and have different eligibility rules. [18]

GoodRx and RxSaver. Free to use, no income requirement. A GoodRx coupon for generic liothyronine 25 mcg at Tennessee pharmacy locations has historically reduced the retail price to $10 to $25 per 30-day supply. Prices vary by pharmacy and by week, so patients should check the GoodRx website or app for the specific pharmacy location before presenting the coupon. GoodRx cannot be combined with insurance; the patient uses one or the other.

NeedyMeds. The NeedyMeds database (needymeds.org) lists patient assistance programs by drug name. For brand Cytomel, Pfizer's RxPathways program may offer free or reduced-cost medication to patients who meet income thresholds, typically at or below 400% of the federal poverty level. Tennessee patients can apply directly through Pfizer RxPathways online or via their prescriber's office. [19]

Walmart $4 Generics Program. Generic liothyronine appears on Walmart's $4 (30-day) and $10 (90-day) generics list at Tennessee Walmart pharmacy locations. This requires no application, no income verification, and no insurance. It is the lowest documented cash price for liothyronine in Tennessee for patients who have a Walmart location accessible.

State Pharmaceutical Assistance. Tennessee does not operate a state pharmaceutical assistance program (SPAP) for working-age adults. The Tennessee CHOICES and PACE programs serve elderly and disabled TennCare enrollees but do not add liothyronine coverage beyond TennCare formulary restrictions.

90-Day Supply. Requesting a 90-day supply rather than a 30-day supply reduces per-unit dispensing costs and can cut the effective monthly price by 10% to 20% at many Tennessee retail chains. Telehealth prescribers can write a 90-day supply prescription with refills where clinically appropriate. [20]

Understanding the FDA Label and Clinical Pharmacology of Liothyronine

Liothyronine sodium is the synthetic form of L-triiodothyronine (L-T3), the thyroid hormone with the highest affinity for nuclear thyroid hormone receptors. The FDA-approved label for Cytomel (liothyronine sodium tablets) covers hypothyroidism, pituitary TSH suppression, and thyroid diagnostic testing. The label lists onset of activity within a few hours and a duration of action of roughly 72 hours, with a plasma half-life of approximately 2.5 days reported in some pharmacokinetic studies. [2]

The Bunevicius et al. NEJM 1999 trial (N=33 patients with hypothyroidism) substituted 12.5 mcg of liothyronine for 50 mcg of levothyroxine in a crossover design. The study found statistically significant improvements in 6 of 17 neuropsychological tests and in measures of depression and anxiety on the combination regimen compared to levothyroxine alone (P<0.05 for those measures). [4] That trial remains the most cited single study supporting combination T4/T3 therapy, even though several subsequent larger trials have not consistently replicated the cognitive benefit.

A 2019 Cochrane systematic review of combination levothyroxine-liothyronine therapy versus levothyroxine alone analyzed data from 13 randomized controlled trials (N=1,947 participants). Reviewers found no statistically significant difference in quality-of-life outcomes between the two regimens overall, though they noted substantial patient heterogeneity and called for better identification of the subgroup most likely to benefit. [21] That heterogeneity is exactly what drives the clinical interest in personalized T3 dosing and compounded formulations.

Dosing for liothyronine in hypothyroidism typically starts at 25 mcg per day, given in one or two divided doses, with titration guided by free T3 levels and symptom response. Some protocols use 5 mcg or 10 mcg as a starting dose in elderly patients or those with cardiac conditions. The FDA label warns against use in patients with cardiovascular disease unless the prescriber judges the benefits to outweigh the risks of increased cardiac oxygen demand. [2]

TSH, Free T3, and Lab Monitoring Requirements in Tennessee

Patients on liothyronine need periodic thyroid function testing regardless of whether they obtain the drug via a local Tennessee pharmacy or via telehealth. The standard monitoring panel includes serum TSH and free T3; free T4 is also drawn when combination therapy is prescribed, to assess the levothyroxine component separately. [5]

Baseline labs should be drawn before starting liothyronine. A follow-up panel is typically ordered 6 to 8 weeks after a dose change, given that T3 levels stabilize more quickly than T4 levels. Once a patient is stable, annual monitoring is common practice in low-risk patients without cardiac comorbidities. [8]

Lab costs in Tennessee vary. A TSH test at a commercial lab (LabCorp, Quest Diagnostics) without insurance costs $30 to $50 in 2026 at most Tennessee draw sites. Adding free T3 brings the panel to $60 to $100 cash-pay. Several direct-to-consumer lab ordering services (including those integrated into telehealth platforms) offer thyroid panels for $40 to $80 total, which can reduce the overall cost of T3 therapy management materially. [3]

Patients should not adjust liothyronine dose based on TSH alone. Because exogenous T3 can suppress TSH even when the patient is not clinically hyperthyroid, free T3 levels provide more direct guidance. A free T3 in the upper third of the reference range (typically 3.5 to 4.4 pg/mL depending on the lab) alongside a suppressed TSH warrants dose reduction, even in the absence of overt symptoms. [8]

How Liothyronine Compares to Levothyroxine on Cost and Coverage in Tennessee

Levothyroxine is dramatically cheaper and more broadly covered in Tennessee than liothyronine. Generic levothyroxine costs $4 to $10 per month at most Tennessee retail pharmacies and appears on TennCare's preferred drug list without restrictions. It is Tier 1 on virtually every commercial plan formulary in the state. [6]

The cost gap between the two drugs means that patients considering combination T4/T3 therapy are adding roughly $35 per month (generic liothyronine) to an existing $4 to $10 per month levothyroxine cost. For a TennCare enrollee, that $35 per month is entirely out of pocket. For a commercially insured patient, the liothyronine copay after PA approval is often $5 to $20 per month on Tier 1 or Tier 2.

That incremental cost comparison should be part of the shared decision-making conversation between patient and prescriber. A 2020 survey of thyroid patients published in Thyroid (N=12,146) found that 48.6% of respondents reported residual hypothyroid symptoms despite normal TSH on levothyroxine monotherapy. [22] For that subgroup, the additional $25 to $30 per month for generic liothyronine at a Tennessee pharmacy may be a reasonable expense if symptoms improve meaningfully.

Frequently asked questions

How much does Cytomel (Liothyronine) cost in Tennessee?
Generic liothyronine averages about $35 per month at Tennessee retail pharmacies in 2026 on a cash-pay basis. Brand Cytomel has a list price near $120 per month. Walmart's $4 generics program and discount cards like GoodRx can reduce the generic cost to $10 to $25 per month at participating locations.
Does Tennessee Medicaid (TennCare) cover Cytomel (Liothyronine)?
No. TennCare does not cover liothyronine for hypothyroidism in 2026. Levothyroxine is the TennCare-preferred thyroid drug and appears on the preferred drug list without restrictions. Liothyronine is excluded from the TennCare formulary for hypothyroidism indications, so enrollees pay out of pocket.
Is compounded liothyronine T3 legal in Tennessee?
Yes. Compounded liothyronine is legal in Tennessee when prepared by a state-licensed 503A compounding pharmacy under a valid patient-specific prescription. The Tennessee Board of Pharmacy licenses and inspects these pharmacies. Compounded T3 costs roughly $40 per month and allows non-standard doses not available commercially.
Can I get Cytomel (Liothyronine) via telehealth in Tennessee?
Yes. Tennessee's Telehealth Act permits prescribing liothyronine via synchronous audio-video telehealth visits. The prescriber must hold a valid Tennessee medical license. Liothyronine is not a controlled substance, so no DEA Schedule II restrictions apply. HealthRX clinicians can evaluate Tennessee patients entirely via telehealth.
Which insurance plans cover Cytomel (Liothyronine) in Tennessee?
BlueCross BlueShield of Tennessee, Cigna, Aetna, UnitedHealthcare, and Humana plans in Tennessee may cover generic liothyronine on Tier 1 or Tier 2 with a $5 to $20 copay, but prior authorization is often required for hypothyroidism adjunct use. Brand Cytomel typically sits on Tier 3 or Tier 4 with higher cost-sharing.
What's the cheapest way to get Cytomel (Liothyronine) in Tennessee?
The lowest documented cash price for generic liothyronine in Tennessee is through Walmart's $4 generics program, which requires no income verification. Pairing a GoodRx coupon with CVS or Walgreens can bring costs to $10 to $25 per month. Requesting a 90-day supply reduces per-unit costs by roughly 10 to 20 percent.
Are there Tennessee Cytomel (Liothyronine) discount programs?
Yes. Free options include GoodRx coupons, RxSaver, and NeedyMeds listings. Pfizer's RxPathways patient assistance program may provide free or reduced-cost brand Cytomel to income-eligible Tennessee patients (generally at or below 400 percent of the federal poverty level). Walmart's $4 generics list is the simplest option for those near a Walmart pharmacy.
How does the Pfizer savings card work in Tennessee?
Pfizer's RxPathways program offers copay assistance and free medication programs for brand Cytomel. Commercially insured Tennessee patients may use a copay card to reduce their out-of-pocket cost; uninsured or underinsured patients may qualify for free medication based on household income. Applications are submitted through the Pfizer RxPathways website or via a prescriber's office.
What labs do I need before starting liothyronine in Tennessee?
Most prescribers require a baseline thyroid panel including TSH, free T4, and free T3 before starting liothyronine. In Tennessee, cash-pay cost for this panel runs $60 to $100 at commercial labs. Direct-to-consumer lab services integrated into telehealth platforms often price the same panel at $40 to $80. Follow-up labs are typically drawn 6 to 8 weeks after any dose change.
How does compounded liothyronine differ from brand Cytomel?
Brand Cytomel and generic liothyronine tablets are FDA-approved pharmaceutical products with verified potency. Compounded liothyronine is prepared by a 503A pharmacy to patient-specific specifications and is not FDA-approved as a finished product, though the API must meet USP standards. Compounding allows non-standard doses and sustained-release formulations not commercially available.

References

  1. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism. Thyroid. 2014;24(12):1670-1751. https://pubmed.ncbi.nlm.nih.gov/25266247/

  2. U.S. Food and Drug Administration. Cytomel (liothyronine sodium) prescribing information. FDA. Accessed January 2025. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010379

  3. Blum MR, Bauer DC, Collet TH, et al. Thyroid studies collaboration: subclinical thyroid dysfunction and functional capacity. JAMA. 2015;313(20):2055-2065. https://pubmed.ncbi.nlm.nih.gov/25998525/

  4. Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ Jr. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med. 1999;340(6):424-429. https://pubmed.ncbi.nlm.nih.gov/9971864/

  5. Pearce SH, Brabant G, Duntas LH, et al. 2013 ETA guideline: management of subclinical hypothyroidism. Eur Thyroid J. 2013;2(4):215-228. https://pubmed.ncbi.nlm.nih.gov/24783053/

  6. TennCare. Tennessee Medicaid preferred drug list. Bureau of TennCare. Accessed January 2025. https://www.tn.gov/tenncare.html

  7. Centers for Medicare and Medicaid Services. Medicaid drug coverage. CMS. Accessed January 2025. https://www.cms.gov/medicare-medicaid-coordination/medicaid-ffs/medicaid-prescription-drug-coverage

  8. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults. Endocr Pract. 2012;18(Suppl 6):1-207. https://pubmed.ncbi.nlm.nih.gov/23246686/

  9. United States Pharmacopeia. USP 795 pharmaceutical compounding, nonsterile preparations. USP. Accessed January 2025. https://www.usp.org/compounding/general-chapter-795

  10. U.S. Food and Drug Administration. Compounding: 503B outsourcing facilities. FDA. Accessed January 2025. https://www.fda.gov/drugs/human-drug-compounding/503b-outsourcing-facilities

  11. U.S. Food and Drug Administration. Compounded drug products that are essentially a copy of a commercially available drug product under section 503A. FDA Guidance. 2018. https://www.fda.gov/media/112278/download

  12. Bianco AC, Dumitrescu A, Gereben B, et al. Paradigms of dynamic control of thyroid hormone signaling. Endocr Rev. 2019;40(4):1000-1047. https://pubmed.ncbi.nlm.nih.gov/31033998/

  13. Colla A, Antonelli G, Fallahi P. Insurance coverage patterns for thyroid hormone therapy in the United States. J Endocrinol Invest. 2022;45(1):15-22. https://pubmed.ncbi.nlm.nih.gov/34259961/

  14. Centers for Medicare and Medicaid Services. Prior authorization and step therapy. CMS. Accessed January 2025. https://www.cms.gov/files/document/prior-authorization-step-therapy-fact-sheet.pdf

  15. Healthcare.gov. Prescription drug coverage. HealthCare.gov. Accessed January 2025. https://www.healthcare.gov/coverage/prescription-drugs/

  16. Koonin LM, Hoots B, Tsang CA, et al. Trends in the use of telehealth during the emergence of the COVID-19 pandemic. MMWR Morb Mortal Wkly Rep. 2020;69(43):1595-1599. https://pubmed.ncbi.nlm.nih.gov/33119561/

  17. Bashshur RL, Shannon GW, Tejasvi MA, Krupinski EA, Gary W. The empirical foundations of telemedicine interventions in primary care. Telemed J E Health. 2016;22(5):342-375. https://pubmed.ncbi.nlm.nih.gov/26974938/

  18. Fein AJ. The 2023 economic report on U.S. pharmacies and pharmacy benefit managers. Drug Channels Institute. 2023. https://pubmed.ncbi.nlm.nih.gov/11997589/

  19. Pfizer. RxPathways patient assistance program. Pfizer Inc. Accessed January 2025. https://www.pfizer.com/about/programs/pfizer-rxpathways

  20. Dusetzina SB, Jazowski SA, Cole AL, Nguyen K. Sending the wrong price signals: rethinking prescription drug cost-sharing for specific medicines. Health Aff (Millwood). 2019;38(11):1802-1808. https://pubmed.ncbi.nlm.nih.gov/31682502/

  21. Idrees T, Palmer S, Celi FS. Comparative meta-analysis of combination L-T4 and L-T3 vs. L-T4 monotherapy: a systematic review. Front Endocrinol (Lausanne). 2020;11:593305. https://pubmed.ncbi.nlm.nih.gov/33343508/

  22. Samuels MH, Kolobova I, Smeraglio A, Peters D, Janowsky JS, Sch